Biogen Idec Inc. fell after demand for its multiple sclerosis drug Tecfidera showed signs of slowing. Prescriptions fell 6.7 percent in the week ended Aug. 2 to 3,377 from the previous week, IMS Health Inc. said. Tecfidera, said Gabelli & Co.’s Kevin Kedra, is “the newest oral MS product . . . It’s gotten off to a very strong launch, so any signs of them maybe slowing down would be a positive for competitors” like Teva Pharmaceutical, Bloomberg reported. Biogen Idec said it doesn’t comment on sales reports.
Biogen Idec slips as MS drug’s sales slow
You have reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week